Three Phase 1 human clinical trials evaluating an Army-developed Zika purified inactivated virus vaccine (ZPIV) have shown it was safe and well-tolerated in healthy adults and induced a robust immune response. Initial findings from the trials have been published in the medical journal ‘The Lancet’. Each of the three studies included in the paper was designed to address a unique question about background immunity, vaccine dose or vaccination schedule. A fourth trial with ZPIV is still underway in Puerto Rico, where the population has natural exposure to other viruses in the same family as Zika (flaviviruses) such as dengue.
Army Testing Zika Vaccine
